Maxim Group Starts Bio-Path Holdings (BPTH) at Buy

Maxim Group initiates coverage on Bio-Path Holdings (NASDAQ: BPTH) with a Buy rating and a price target of $5.00.

Analyst Pamela Bassett comments, "Bio-Path, with its proprietary liposome-antisense technology platform enabling systemic delivery of its own next-generation antisense, is a potential product engine. Bio-Path’s focus is cancer, and we expect the company to pursue a broad licensing strategy. Valuations of companies pursuing RNA-focused therapeutics have increased substantially, and we believe Bio-Path remains an undiscovered opportunity with upcoming catalysts that we think could drive the valuation higher, more in line with its RNA-focused therapeutics peer companies."

For an analyst ratings summary and ratings history on Bio-Path Holdings click here. For more ratings news on Bio-Path Holdings click here.

Shares of Bio-Path Holdings closed at $2.66 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy